Evaxion picks gonorrhea as second target for vaccine candidate

Evaxion Biotech has announced that the firm has chosen sexually transmitted disease gonorrhea as the second target of its EVX-B2 vaccine candidate.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Evaxion Biotech's lung cancer candidate ready for clinic
For subscribers
GSK to invest USD 1.2bn in infectious disease battle
For subscribers